An Open Label, Single Arm Phase IIb Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer
Latest Information Update: 30 May 2025
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ReaLuP
Most Recent Events
- 23 May 2025 Status changed from not yet recruiting to recruiting.
- 18 Mar 2025 New trial record